



Three Moves Ahead: Strategic Sequencing Approaches for Patients With HER2+ Metastatic Breast Cancer

MONDAY, 16 SEPTEMBER 2024 | 13:00–14:30 CEST

Pamplona Auditorium, Hall 3, Fira Barcelona Gran Via, Barcelona, Spain

OVERVIEW

Join renowned experts Drs Ciruelos, McArthur, Frenel, and Bianchini and hear stimulating conversations on how to best navigate treatment sequencing for patients with HER2+ metastatic breast cancer (MBC).

In this engaging and interactive symposium, the expert panel will discuss current guidelines and the latest treatment data for HER2+ MBC enhanced with case-based scenarios. Gain practical knowledge on the clinical implementation of treatment sequencing, with a special focus on disease progression and central nervous system (CNS) involvement.

AGENDA

Welcome and Introduction

Opening Moves: How Has the Therapeutic Landscape Evolved for HER2+ MBC?

What Is Your Defence Strategy? Clinical Decision-Making Against CNS Involvement in HER2+ MBC

What Is Your Strategic Move? Clinical Decision-Making in 3L HER2+ MBC


Mastering Future Moves: Opportunities in HER2+ MBC

Panel Discussion and Audience Q&A

Closing Remarks


SPEAKERS

CHAIR



Eva Ciruelos, MD, PhD
Medical Oncology Unit
Hospital 12 de Octubre
Madrid, Spain

PANELISTS



Heather McArthur, MD
Department of Internal Medicine
Division of Hematology-Oncology
University of Texas Southwestern Medical Center
Dallas, Texas, United States



Jean-Sébastien Frenel, MD, PhD
Medical Oncology Department
Institut de Cancérologie de l'Ouest
Site René Gauducheau, Saint-Herblain
Nantes, France



Giampaolo Bianchini, MD
Vita-Salute San Raffaele University
Department of Medical Oncology
Ospedale San Raffaele
Milano, Italy